Celltrion Pharma achieved record quarterly earnings, driven by the success of biosimilars (replica biopharmaceuticals) and increased contract manufacturing organization (CMO) revenue.
The company said Monday that its Q3 revenue reached 161.9 billion won and operating profit was 23.9 billion won, representing year-on-year increases of 17.2% and 48.4%, respectively. Both revenue and operating profit marked all-time quarterly highs.
Cumulative Q3 revenue rose 17.1% year-on-year to 447.3 billion won, while operating profit increased by 32.4% to 56.1 billion won. Notably, operating profit surpassed last year’s full-year operating profit (56.1 billion won) within just three quarters. Analysts assess that the company is highly likely to surpass last year’s annual revenue of 536.4 billion won and set another all-time high in sales.
In detail, the chemical pharmaceutical segment generated total revenue of 68.4 billion won. Key products continued stable performance: the intravenous solution “Godecs” recorded 17.7 billion won in revenue, up 10.3% year-on-year, while the hypertension treatment “Dilatren” posted 15.8 billion won, a 5.5% increase.
The combination drug for hypertension and hyperlipidemia, “Amrojet,” achieved 600 million won in revenue, surging 355.9% year-on-year due to expanded prescriptions.
Biopharmaceutical segment revenue totaled 45.2 billion won, a 40.2% increase from the same period last year. Growth was driven by securing new prescriptions at major hospitals and expanding sales within existing prescription channels.
The autoimmune disease treatment “Rhemys” recorded 14.9 billion won in revenue, up 18.8%, boosted by approval for increased dosing of its pen-type product. “Uplima” posted 2.9 billion won, a 54.1% increase. The anticancer drugs “Herzuma” and “Truxima” recorded revenues of 5.1 billion won and 4.1 billion won, respectively, representing increases of 17.8% and 64.0%. “Vegzelma” achieved 3.6 billion won in revenue, a 9.4% rise.
New product lines launched domestically last year also continued to deliver results. The bone disease treatment “Stoboclo” generated 7.7 billion won in revenue, up 64.5% year-on-year. The ophthalmic disease treatment “Idengelt” recorded 4.1 billion won, a 149.1% growth, while the allergic disease treatment “Omriclo” posted 1.7 billion won, a 64.8% increase. Autoimmune disease treatments “Stecima” and “Aptozuma” each generated 500 million won in revenue, signaling the beginning of substantial performance.
The contract manufacturing segment achieved 48.2 billion won in revenue, a 26.2% year-on-year increase. In particular, commercial production revenue reached 40.4 billion won, up 44.2%, driven by maximum operation of the pre-filled syringe (PFS) production facility, leading the segment’s growth.
A company official said, “Robust sales of key products, expanded prescriptions for biopharmaceuticals, and strong performance in PFS contract manufacturing combined to drive both revenue and operating profit to record quarterly highs.” The official added, “We will make every effort to sustain this growth momentum through year-end to achieve meaningful results.”
in THEBIO
